[Sequential changes in blood concentrations of tegafur and 5-FU during oral administration of fine granules of tegafur in patients with primary liver cancer].
Tegafur fine granule preparation orally administered to the patients with primary hepatoma and liver cirrhosis, and the concentration of tegafur and 5-fluorouracil in the blood were determined. The concentration of tegafur in blood was maintained well in the injured liver, and remained same 3 weeks after administration of tegafur fine granules. The concentration of 5-fluorouracil in the blood decreased distinctly when the dysfunction of the liver was severe (KICG less than 0.070). In the case of malignant disease with the injured liver, oral administration or tegafur might be less effective. However, the concentration of 5-fluorouracil in the blood did not decrease 3 weeks after administration of tegafur fine granules. No cases showed noticeable clinical effects by only oral administration.
D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000097:blood*; D006528:Carcinoma, Hepatocellular / Q000097:blood; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives* / Q000097:blood*; D006801:Humans; D008103:Liver Cirrhosis / Q000097:blood; D008113:Liver Neoplasms / Q000097:blood* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D005641:Tegafur / Q000008:administration & dosage / Q000097:blood*
D000970:Antineoplastic Agents; D005641:Tegafur; D005472:Fluorouracil